Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.39 |
| ▸ | GRPR | P30550 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 6/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314402 | 0.89 | SLC15A2 (0.69) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL15134133 | 0.85 | SLC15A2 (0.51) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| Acetic Acid SCHEMBL29453855 | 0.80 | SLC15A2 (0.59) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL15185869 | 0.80 | SLC15A2 (0.56) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL26006164 | 0.78 | SLC15A2 (0.70) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL15186059 | 0.78 | SLC15A2 (0.55) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL15186031 | 0.78 | SLC15A2 (0.55) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL15185951 | 0.78 | SLC15A2 (0.55) | SLC15A2SLC6A5TLR2FAAHCNR1 | |
| SCHEMBL18857761 | 0.76 | SLC15A2 (0.58) | SLC15A2SLC6A5 | |
| SCHEMBL29875979 | 0.75 | SLC15A2 (0.67) | SLC15A2SLC6A5FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NSUN3, RNMT, AGO2 | SLC15A2 1608/4885SLC6A5 4502/4885TLR2 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.